LL-37 vs Lactoferricin

Overview

LL-37 and Lactoferricin are both cationic antimicrobial peptides with broad-spectrum activity, but they have different origins. LL-37 is the endogenous human cathelicidin produced by immune cells and epithelia, while Lactoferricin is derived from the N-terminal region of lactoferrin, an iron-binding protein found in milk and mucosal secretions. Both show promise as antimicrobial and immunomodulatory agents.

Key Facts

Aspect	LL-37	Lactoferricin
Type	Human cathelicidin	Lactoferrin derivative
Origin	Endogenous human	Bovine or human lactoferrin
Structure	37 amino acids	25 amino acids (LfcinB)
Precursor	hCAP-18	Lactoferrin
Natural Source	Neutrophils, epithelia	Milk, mucosal secretions
FDA Status	Not approved	Not approved

Origin and Production

Aspect	LL-37	Lactoferricin
Human/Animal	Human	Bovine (LfcinB) or Human (LfcinH)
Production	Endogenous synthesis	Pepsin cleavage of lactoferrin
In Vivo	Yes	Yes (digestive processing)
Commercial	Synthetic	Synthetic or enzymatic

LL-37 Origin

• C-terminal fragment of hCAP-18
• Cleaved by proteinase 3
• Produced in neutrophils, epithelia
• Induced during infection/inflammation

Lactoferricin Origin

• N-terminal region of lactoferrin
• Released by pepsin digestion
• Bovine (LfcinB) most studied
• Human (LfcinH) also exists

Structure Comparison

Aspect	LL-37	Lactoferricin B
Length	37 amino acids	25 amino acids
Secondary Structure	Alpha-helix	Loop/beta-hairpin
Disulfide Bonds	None	1 (Cys19-Cys36 LF numbering)
Net Charge	+6	+8
Amphipathic	Yes	Yes

Mechanism Comparison

Aspect	LL-37	Lactoferricin
Primary Action	Membrane disruption	Membrane disruption
LPS Binding	Yes	Yes
Immunomodulation	Strong	Moderate
Iron-Related	No	Some (from lactoferrin)

LL-37 Mechanisms

1. Direct Antimicrobial

   • Membrane permeabilization
   • Toroidal pore model
   • Broad spectrum activity
   • Biofilm penetration

2. Immunomodulation

   • Chemotaxis of immune cells
   • Cytokine modulation
   • Wound healing promotion
   • Anti-endotoxin effects

3. LPS Neutralization

   • Binds lipopolysaccharide
   • Reduces inflammatory response
   • Prevents septic cascade

Lactoferricin Mechanisms

1. Direct Antimicrobial

   • Membrane disruption
   • Electrostatic binding to bacteria
   • Lipid bilayer destabilization
   • Rapid bactericidal action

2. Additional Activities

   • Antifungal effects
   • Antiparasitic activity
   • Antiviral (some viruses)
   • Anti-tumor properties

3. Immunomodulatory

   • Cytokine modulation
   • Macrophage activation
   • Anti-inflammatory effects

Antimicrobial Spectrum

LL-37 Activity

Pathogen	Activity
Gram-positive	Strong
Gram-negative	Strong
Fungi	Moderate
Biofilms	Active
Enveloped viruses	Some

Lactoferricin Activity

Pathogen	Activity
Gram-positive	Strong
Gram-negative	Strong
Fungi (Candida)	Strong
Parasites	Some
Viruses	Some

Comparative Efficacy

Factor	LL-37	Lactoferricin
MIC range	Variable	Often lower
Speed of killing	Rapid	Very rapid
Biofilm activity	Yes	Yes
Synergy with antibiotics	Demonstrated	Demonstrated

Evidence Quality

Factor	LL-37	Lactoferricin
In Vitro Studies	Extensive	Extensive
Animal Studies	Multiple	Multiple
Human Studies	Very few	Very few
Safety Data	Limited	Limited
Overall Evidence	Low-Moderate	Low

Research Volume

Aspect	LL-37	Lactoferricin
Publications	>5000	>500
Clinical trials	Very few	Very few
Therapeutic development	Early	Early

Therapeutic Potential

LL-37 Applications

Area	Status
Wound infections	Preclinical
Respiratory infections	Early research
Sepsis	Interest
Topical formulations	Being developed

Lactoferricin Applications

Area	Status
Oral health	Some products
Topical antimicrobial	Research
Food preservation	Interest
Cancer research	Early

Safety and Toxicity

LL-37

Concern	Note
Hemolysis	Dose-dependent
Host cell toxicity	At high concentrations
Pro-inflammatory	In some contexts (psoriasis)
Therapeutic window	Narrow

Lactoferricin

Concern	Note
Selectivity	Better than some AMPs
Host toxicity	Lower than LL-37
Food-derived	May suggest safety
Hemolysis	Lower

Administration Considerations

Factor	LL-37	Lactoferricin
Stability	Poor (proteases)	Moderate
Oral Availability	Poor	Poor
Topical	Being studied	More feasible
Cost	High	Moderate

Stability Improvements

Approach	LL-37	Lactoferricin
D-amino acids	Tested	Tested
Cyclization	Tested	Tested
Truncation	LL-37 fragments	Shorter analogs
PEGylation	Being developed	Being developed

Natural vs Derivative

Factor	LL-37	Lactoferricin
Endogenous	Yes (human)	No (cleavage product)
Present in body	Yes	Yes (after milk digestion)
Physiological role	Innate immunity	Antimicrobial defense
Therapeutic logic	Augment natural defense	Use natural fragment

Regulatory Status

Aspect	LL-37	Lactoferricin
FDA Approval	None	None
Drug Development	Early stage	Early stage
Food/Supplement	N/A	Lactoferrin supplements exist
Research Chemical	Available	Available

Summary

Factor	LL-37	Lactoferricin
Origin	Human cathelicidin	Lactoferrin-derived
Length	37 amino acids	25 amino acids
Structure	Alpha-helix	Loop structure
Charge	+6	+8
Immunomodulation	Strong	Moderate
Selectivity	Moderate	Better
Evidence Level	Moderate	Low

Key Takeaways

1. Different origins: LL-37 is endogenous human; lactoferricin from milk protein
2. Both cationic AMPs: Similar antimicrobial mechanism (membrane disruption)
3. LL-37 has more research: Greater publication volume and interest
4. Lactoferricin may be safer: Better selectivity, lower host toxicity
5. Neither approved: Both in early therapeutic development
6. Both have stability issues: Require modifications for therapeutic use
7. LL-37 stronger immunomodulator: More documented immune effects
8. Lactoferricin food-derived: May offer safety/acceptability advantage

---

This comparison is for educational purposes only. Neither peptide is approved for therapeutic antimicrobial use. Both are research compounds.